Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-08-01 00:00:00 ET · period of report 2024-07-30 · accession 0000875320-24-000195 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-01 | 2024-07-30 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $505.00 | -15.2K | 91.0K | -14% | -$7.68M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-30 | S | D | 15,202 | $505.00 | 90,970 | D | — | — |